Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection

Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection

Item

http://www.wikidata.org/entity/Q28262594

Q28262594

about

Virological Mechanisms in the Coinfection between HIV and HCV Lack of response to exogenous interferon-α in the liver of chimpanzees chronically infected with hepatitis C virus Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection Lessons from rare tumors: hepatic lymphoepithelioma-like carcinomas Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production.Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review.Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis.Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.Benzylideneacetophenone derivatives attenuate IFN-γ-induced IP-10/CXCL10 production in orbital fibroblasts of patients with thyroid-associated ophthalmopathy through STAT-1 inhibition.Profiles of acute cytokine and antibody responses in patients infected with avian influenza A H7N9 Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon Ribavirin improves early responses to peginterferon through improved interferon signaling Lethal Nipah virus infection induces rapid overexpression of CXCL10.The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10.The CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows dys-regulated activity in hepatitis C Chemokine antagonism in chronic hepatitis C virus infection Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B Evaluation of IL-28B polymorphisms and serum IP-10 in hepatitis C infected chimpanzees.Detection of respiratory viruses and the associated chemokine responses in serious acute respiratory illness.Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection Controversies in and challenges to our understanding of hepatitis C.Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.Clinical implications of chemokines in acute and chronic hepatitis C virus infection.Serum IP-10 Levels Correlate with the Severity of Liver Histopathology in Patients Infected with Genotype-1 HCV.The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C.Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.Predictive factors associated with hepatitis C antiviral therapy response.Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin.Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection

P2860

Q26780313-82C74686-146E-4694-BD84-3F3A95AA1C10 Q27486088-22413D62-3057-40AB-810D-B6217E1EA7CE Q27490393-57178586-B7CA-4AF8-A23F-9BE3A3721A0C Q28087354-B20082B9-F9E2-4850-AE81-C5C7B2123D06 Q28274298-F3F068E3-B21C-40C1-9C9D-3F40D43DF3CF Q28287283-19E3F6D3-339C-4217-B5C7-6B4571EB111D Q28539645-D39D24CB-80D7-4AE6-AB7B-2C474EF65612 Q29615959-E0E18A4A-6472-4FD1-AC7F-475DC6A37589 Q30416248-9963EFEC-4ABF-4081-995C-DBB23371CA4E Q33365130-0DB27839-AA82-487A-BAB7-96DAF62174C5 Q33706737-78D75B0E-AE4C-4732-ADC5-12E9C21960EE Q33745372-BCDA48F1-B090-44FF-B37A-7A38F4DEB7B6 Q33797446-4B61A5F5-BB9F-49E7-AD4C-CD197CAA1ADE Q33816657-85797B59-A033-4A0F-9DEE-94BDE290402B Q33842239-32185E96-D9D9-4B83-9010-99DD753ECA6C Q33844846-8963DBC3-A5DF-4B83-B463-BD632ACD51AD Q33864111-DDBF60F9-A247-4E6C-BB18-0E21489B735A Q33877898-79A4DCC9-F304-4929-AEF6-C218A94B4C1A Q33987120-1281AF93-C6DF-4085-B7BA-07F527461F9A Q34185782-47C0B6E0-0A44-4E40-B0BE-C3209F6CCC23 Q34218503-29B2636D-E4DF-4E22-A333-9D16AA5A23EE Q34335634-6AA9D6FF-F60A-4347-8B6D-0D5489746DE9 Q34429056-487D9128-7E83-400A-8535-4974BE191735 Q34450653-05498D0C-8A9F-4455-BC3F-4644F3F4F11F Q34464406-8311D80C-9410-41EE-B4E4-9962EF96B73E Q34477691-5AD0777D-5DE8-4BFA-9449-44899C6485A7 Q34599847-0A4FAC04-A46D-4218-B8C6-E208FE42AE03 Q34604806-565A48B2-DF56-4813-800E-73184D0DE706 Q34867045-839A202F-1249-4975-A154-3F74749FA7CA Q35053399-F5718597-DC56-4991-BA27-8659CE2E66E5 Q35065912-5AE150F1-937F-432C-80FB-C086FB5788DE Q35561908-9FEBBA7D-B592-40AF-AF4C-7C399451EFD2 Q35619177-E6E3939B-5B03-4082-8DC2-4E079DDE5CA6 Q35675852-77C62161-5935-40D2-B100-8AC877B7C2C3 Q35693436-8F0B0F7B-93C6-4899-A987-73E7B7763BD5 Q35764450-E71B4340-21DF-4D16-8601-A4C361116798 Q35790397-FAF1A998-EC5A-49BC-800A-5071BA17874F Q35862941-CEDD83E0-3909-4C7C-A627-DA2EE9D36A60 Q35947900-DA5CE4FF-72B5-4F32-ABA8-67D969DCCBFD Q36014286-F4080BBC-DE74-459B-B165-9B504174C52E

P2860

Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection

Item

http://www.wikidata.org/entity/Q28262594

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu